Commercial real estate services firm Colliers International Group Inc. announced Tuesday it has secured a long-term lease at the former Bristol-Myers Squibb campus in Plainsboro.
Genmab A/S, a biotechnology company specializing in the treatment of cancer, will be relocating its U.S. headquarters and establish a research lab within the 125-acre corporate campus at 777 Scudders Mill Road.
Colliers said Genmab will be the first new tenant at the campus since Bristol-Myers relocated. It will move into 90,070 square feet across two floors.
Charlie Hatfield, executive managing director and New Jersey life sciences practice leader at Colliers; Brett Incollingo, associate director; and Tom Romano of JLL; represented the property owner, Trawler Capital Management in the deal. Dan Spera and Craig Eisenhardt, managing directors at JLL; and Jason Benson, vice president; represented Genmab.
“The combination of working with a well-funded and transaction oriented owner, who controls the best quality product in the market, and is tenant and broker friendly is always a winning combination in the very competitive world of attracting and retaining world class tenants like Genmab,” Hatfield said.
Located in the Princeton/Route 1 submarket, 777 Scudders offers its tenants a suite of amenities, including all new conference and meeting spaces, private and reservable wellness rooms, bike and pedestrian paths, an outdoor amphitheater, a media lab, electric car charges, a cafeteria, and more.
“We are pleased to be part of the 777 Scudders Mill Road campus environment, which supports our ambitions to nurture Genmab’s corporate culture in a new and vibrant workplace environment that aligns with our company vision,” Chris Cozic, corporate vice president of human resources, Genmab, said. “New Jersey’s ever-dynamic and innovative life-sciences ecosystem, along with the high-skilled labor market in the state, made the campus an ideal location to continue our growth trajectory.”